Skip to navigation Skip to content

News

Share

An FDA Approved Generic Form of Ampyra® (dalfampridine) Is Launched in the U.S.

October 19, 2018

A generic equivalent of Ampyra (dalfampridine), a treatment that is approved to improve walking in adults with MS, has been approved by the U.S. Food and Drug Administration and launched by Mylan NV. Dalfampridine extended-release tables 10 mg are currently available. Details on price have not been provided.

Dalfampridine is approved by the FDA to improve walking in people with MS. Possible adverse events include seizures, urinary tract infection, nausea, dizziness, insomnia and upper respiratory tract infection. This approval means that Mylan provided evidence that this generic medication is equivalent to Ampyra.

Selecting a therapy should be done by people with MS in collaboration with their MS doctors, taking into account a variety of factors, including the effectiveness of any therapy they are currently using, and weighing potential risks and benefits, costs and lifestyle factors.

Read more
Read the dalfampridine medication guide for patients
View the dalfampridine prescription label
 
Frequently Asked Questions: Generic and Biosimilar - Medications

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. There is currently no cure for MS. Symptoms vary from person to person and range from numbness and tingling, to mobility challenges, blindness and paralysis. An estimated 1 million people live with MS in the United States. Most people are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

About the National Multiple Sclerosis Society

The National MS Society, founded in 1946, funds cutting-edge research, drives change through advocacy, and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, Twitter, Instagram, YouTube or 1-800-344-4867.

Share


© 2021 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.